GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Notes Receivable

AngioLab (XKRX:251280) Notes Receivable : ₩0.0 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is AngioLab Notes Receivable?

AngioLab's Notes Receivable for the quarter that ended in Dec. 2023 was ₩0.0 Mil.


AngioLab Notes Receivable Historical Data

The historical data trend for AngioLab's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Notes Receivable Chart

AngioLab Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

AngioLab Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable Get a 7-Day Free Trial - - - - -

AngioLab Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


AngioLab Notes Receivable Related Terms

Thank you for viewing the detailed overview of AngioLab's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioLab (XKRX:251280) Business Description

Traded in Other Exchanges
N/A
Address
65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines